Skip to main content
BioArctic logo

BioArctic — Investor Relations & Filings

Ticker · BIOA ISIN · SE0010323311 LEI · 549300Y0OI2WVUNHLC33 ST Professional, scientific and technical activities
Open in API
Filings indexed 444 across all filing types
Latest filing 2026-04-29 Earnings Release
Country SE Sweden
Listing ST BIOA

About BioArctic

https://www.bioarctic.se/en/

BioArctic is a research-intensive biopharmaceutical company focused on developing disease-modifying treatments, biomarkers, and diagnostics for neurodegenerative diseases. The company's core strategy is based on its proprietary antibody technology, which develops unique treatments that target the misfolded and aggregated proteins considered to be the underlying cause of disorders such as Alzheimer's and Parkinson's disease. Through strategic partnerships with global pharmaceutical companies, BioArctic advances its innovative therapies from research through clinical development and commercialization, aiming to address significant unmet medical needs in neurology.

Recent filings

Filing Released Lang Actions
Sales of Leqembi® totaled 26.2 billion yen in the first quarter 2026
Earnings Release Classification · 87% confidence The document is a press release announcing preliminary first quarter 2026 sales figures for Leqembi® and the resulting royalty to BioArctic. It provides key highlights of Q1 results (sales and royalty numbers) without full financial statements or detailed analysis. This matches the definition of an Earnings Release (ER): an initial announcement of quarterly financial results with highlights only. Q1 2026
2026-04-29 English
Notice of Annual General Meeting 2026 in BioArctic AB (publ)
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a formal notice to shareholders of BioArctic AB’s Annual General Meeting 2026, including the meeting date, venue, registration instructions, voting procedures (postal voting, proxy), detailed agenda items, board and auditor elections, dividend proposal, and other resolutions. It is not a presentation made during the AGM (AGM-R), nor the full annual report (10-K), nor an earnings release (ER), nor a results declaration (DVA). Instead, it constitutes the proxy solicitation/information materials sent to shareholders to request their votes and inform them of proposals. Therefore, it fits the definition of a Proxy Solicitation & Information Statement (PSI).
2026-04-21 English
Kallelse till årsstämma 2026 i BioArctic AB (publ)
Proxy Solicitation & Information Statement Classification · 86% confidence The document is a formal notice (kallelse) to shareholders for the 2026 Annual General Meeting of BioArctic AB (publ). It provides meeting date, registration details, agenda with proposals, voting instructions (including proxy and postal voting procedures), and items requiring shareholder approval. This aligns with the definition of a Proxy Solicitation & Information Statement (PSI), i.e. materials sent to shareholders to inform them of agenda items and solicit their votes for an upcoming meeting.
2026-04-21 Swedish
Annual Report 2025
Annual Report Classification · 100% confidence The document is titled 'BIOARCTIC Årsredovisning och hållbarhetsrapport 2025', which translates to 'BioArctic Annual Report and Sustainability Report 2025'. It contains detailed sections including financial overview, management commentary (Vd har ordet), research and strategy, financial reports, governance, and sustainability report. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content includes comprehensive financial data, management discussion, and sustainability information, consistent with an official yearly report covering company activity and full financial performance. Therefore, this document fits the definition of an Annual Report (10-K). FY 2025
2026-04-21 Swedish
Annual Report 2025
Annual Report Classification · 100% confidence The document is titled 'BioArctic Årsredovisning och Hållbarhetsrapport 2025', which translates to 'Annual Report and Sustainability Report 2025'. It contains detailed financial data such as net sales, royalties, operating results, and cash flows for the year 2025, as well as a comprehensive table of contents including financial reports, management commentary, governance, and sustainability sections. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of audited financial statements and signatures further supports this. Therefore, this document is the official yearly report covering company activity and full financial performance, fitting the definition of an Annual Report (10-K). FY 2025
2026-04-21 Swedish
Valberedningens förslag till val av styrelseledamöter och styrelseordförande i BioArctic AB
Board/Management Information Classification · 92% confidence The document is a press release from BioArctic AB’s nomination committee announcing its proposal for the composition and election of the board of directors and chairman at the upcoming Annual General Meeting. It provides detailed biographies of proposed board members, outlines committee composition and independence, and directs shareholders to further information upon the official meeting notice. This is an announcement concerning changes to the company’s board, matching the Board/Management Information category (MANG).
2026-03-27 Swedish

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.